Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 2/20 | 0.36 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 8/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.34 |
| ▸ | USP2 | O75604 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19992848 | 0.92 | TSHR (0.36) | ITGB3ITGA2BCYP2D6TSHRCYP3A4 | |
| SCHEMBL19992739 | 0.92 | ITGB3 (0.40) | ITGB3ITGA2BCYP2D6TSHRHSD17B10 | |
| SCHEMBL20793670 | 0.90 | HRH3 (0.36) | ITGB3ITGA2BCYP2D6TSHRHSD17B10 | |
| SCHEMBL20793497 | 0.90 | TSHR (0.35) | ITGB3ITGA2BCYP2D6TSHRHSD17B10 | |
| SCHEMBL20793504 | 0.87 | ITGB3 (0.39) | ITGB3ITGA2BCYP2D6TSHRHSD17B10 | |
| SCHEMBL20793672 | 0.85 | HRH3 (0.38) | ITGB3ITGA2BCYP2D6TSHRHSD17B10 | |
| SCHEMBL20793493 | 0.81 | ITGB3 (0.38) | ITGB3ITGA2BCYP2D6TSHRHSD17B10 | |
| SCHEMBL20793975 | 0.81 | TSHR (0.42) | ITGB3ITGA2BCYP2D6TSHRHSD17B10 | |
| SCHEMBL20793591 | 0.80 | OPRD1 (0.35) | TSHR | |
| SCHEMBL14671193 | 0.80 | ITGB3 (0.42) | ITGB3ITGA2BCYP2D6TSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | H. LUNDBECK A/S (DK) | 2021-11-02 | — | — | US | disclosed |
| EP-3515897-B1 | PIPERAZINE CARBAMATES AS MODULATORS OF MAGL AND/OR ABHD6 AND THEIR USE | H LUNDBECK AS (DK) | 2021-08-18 | — | — | EP | disclosed |
| US-20210214375-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2021-07-15 | — | — | US | disclosed |
| US-20190202801-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | H. LUNDBECK A/S (DK) | 2019-07-04 | — | — | US | disclosed |
| WO-2019046330-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
| WO-2018053447-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABIDE THERAPEUTICS, INC. (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11161856-B2 | Spirocycle compounds and methods of making and using same | OPRL1, MGLL, VKORC1L1 | ITGB3 4443/4885ITGA2B 4042/4885CYP2D6 459/4885 |
| US-20190202801-A1 | PIPERAZINE CARBAMATES AND METHODS OF MAKING AND USING SAME | ABHD6, RABL6, ABHD16A | ITGB3 4660/4885ITGA2B 4802/4885CYP2D6 386/4885 |
| US-20210214375-A1 | SPIROCYCLE COMPOUNDS AND METHODS OF MAKING AND USING SAME | OPRL1, MGLL, OPRK1 | ITGB3 4097/4885ITGA2B 4048/4885CYP2D6 947/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.